Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078262 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2766878 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14929468 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13722079 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13978164 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2157170 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2511160 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2157176 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13976549 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5558240 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | claimed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | claimed |
| WO-2026102333-A1 | METHODS OF TREATING CARDIOMYOPATHY USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739778-A2 | RNA MOLECULE | Imperial College Innovations Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735051-A1 | COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4720339-A1 | METHODS FOR DOUBLE-STRANDED SEQUENCING BY SYNTHESIS | Illumina, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4713459-A2 | ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF | LIFORDI IMMUNOTHERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260060996-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2026-03-05 | — | — | US | disclosed |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6770748-B2 | ANTISENSE AGENTS FOR AIDS; IMMOBILIZED CONFORMATION OF THE SUGAR PORTION OF NUCLEIC ACID | Imanishi, Takeshi (JP) | 2004-08-03 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030144231-A1 | Oligonucleotide analogues | EXIQON A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | TAKESHI IMANISHI (JP) | 2003-06-05 | — | — | US | disclosed |
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2002-06-06 | — | — | US | disclosed |
| US-6268490-B1 | NUCLEOSIDE ANALOG; FOR ANTISENSE AGENT WHICH IS HYDROLASE RESISTANT, HAS HIGH SENSE STRAND BINDING ABILITY AND IS EASILY SYNTHESIZED | TAKESHI IMANISHI (JP) | 2001-07-31 | — | — | US | disclosed |
| EP-1013661-A1 | NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUES | Imanishi, Takeshi (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | DCLRE1B, TARBP1, NCL | SLC28A1 111/4885SLC28A2 132/4885SLC29A1 52/4885 |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | MYLK2, PRKCG, PRKAG2 | SLC28A1 804/4885SLC28A2 225/4885SLC29A1 1039/4885 |
| US-20260060996-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | UPF1, FUS, TFRC | SLC28A1 532/4885SLC28A2 375/4885SLC29A1 297/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | SLC28A1 126/4885SLC28A2 142/4885SLC29A1 53/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | SLC28A1 129/4885SLC28A2 79/4885SLC29A1 106/4885 |
| US-20030144231-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | SLC28A1 126/4885SLC28A2 142/4885SLC29A1 53/4885 |
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | DCLRE1B, POLA1, POLB | SLC28A1 215/4885SLC28A2 269/4885SLC29A1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.